Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Gedeon Richter — Q4 2025 Earnings Presentation
67 slides from Chemical Works Of Gedeon Richter's earnings presentation, February 2026
Slide 1: Investor presentation
Investor presentation February 2026
Slide 2: Richter at a glance
Richter at a glance 120+ Years ~11,500 8 41 EUR 2.3bn history employees manufacturing commercial and sales revenue in 2025, sites marketing in 4 business units companies 666 Neuropsychiatry | CNS 826 Vraylar® 200+ 2nd position EUR ~5.7bn Women’s healthcare |WHC 21st best-selling molecules in Women's
Slide 3: Our Vision for 2035
Our Vision for 2035 We improve quality of life globally with a special focus on women and mental health patients We concentrate on the development, Innovative manufacturing and commercialization of Pharma pharmaceuticals Global recognition & only Affordable Our innovative solutions elevate therapeut
Slide 4: Innovative and Affordable approach driven by therapeutic area focus
Innovative and Affordable approach driven by therapeutic area focus INNOVATIVE AFFORDABLE We aspire to become thought leaders globally and to build Our aim is to provide reasonably priced products a portfolio of leading therapies accessible to a wide range of people, ensuring equitable access and su
Slide 5: Multiple levers of Revenue growth and Margin improvement
Multiple levers of Revenue growth and Margin improvement 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Maximizing potential of current portfolio and indications (Contraception, Endometriosis, Fertility, Menopause) 2nd wave of 1st wave of new products in existing segments new products and PC
Slide 6: Women’s Healthcare
Women’s Healthcare WHC 6 6
Slide 7: WHC to become the largest cEBIT contributor by 2035
WHC to become the largest cEBIT contributor by 2035 EXPAND THERAPEUTIC SEGMENTS DOUBLE REVENUE THOUGHT LEADERS IN WOMEN'S HEALTHCARE Focus on growth of established TAs Double Revenue, double R&D (Contraception, Fertility, Endometriosis, investment, and improve EBIT margin Address unmet medical needs
Slide 8: Women’s Healthcare – rich in history, full of ambitions
Women’s Healthcare – rich in history, full of ambitions Foundation Expansion Acceleration 1901 1902 1908 1930 1966 1994 2010 2010 2013 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 Crystaline oestron Publicly Lenzetto® innovative License and supply Acquisition of Evra License and supply Fou
Slide 9: WHC at a glance at Richter
WHC at a glance at Richter Global WHC Revenue (EUR mn) Europe WHC market share Global WHC Coverage Contraception Market share compared GEDEON RICHTER Fertility 826 to the market lead Menopause 70 competitor (%) 724 Endometriosis 669 48 111 75 73% Others 42 68 582 40 81 33 42 62 70 69% 22 83 461 34 1
Slide 10: Seven strategic Therapeutic segments defined in WHC
Seven strategic Therapeutic segments defined in WHC Our traditional Therapeutic segments New strategic Therapeutic segments Women’s Contraception Endometriosis Menopause Fertility Urinary tracts PCOS oncology Largest WHC Key strategic Recent co High growth- Major diseases Leading Most attractive rev
Slide 11: Contraception — the leading provider in Europe
Contraception — the leading provider in Europe Market potential and position Our product portfolio European market share (%) in regular ◼ Oral contraception (in cycles) ◼ Among the 1.9bn women of contraceptives GEDEON RICHTER Competitor 2 Competitor 4 reproductive age (15–49 years) Drovelis: License
Slide 12: Fertility — a broad portfolio for infertility specialists
Fertility — a broad portfolio for infertility specialists Market potential and position Our product portfolio Age-related decline in infertility in women and men8 ◼ r-hFSH* ◼ Global sales of infertility treatment 1.0 women are estimated to be USD 1.9bn in men 2024 and are anticipated to reach 0.8 Be
Slide 13: Menopause — protected brands on a high-growth market
Menopause — protected brands on a high-growth market Market potential and position Our product portfolio The growth of menopause market in Europe (EUR mn) ◼ Menopause is an area of high unmet ◼ Transdermal delivery 180 need globally. 160 ◼ Based on the age distribution of the 140 population and shar
Slide 14: Endometriosis — leading original therapy
Endometriosis — leading original therapy Market potential and position Our product portfolio Number of patients treated with Ryeqo® ◼ Globally, 190mn women are ◼ Original GnRH antagonist combination 100 000 Endometriosis suffering from endometriosis. indication Currently no cure exists, and 80 000 t
Slide 15: Pipeline delivery built on the Innovative research hubs
Pipeline delivery built on the Innovative research hubs Richter R&D Innovation center – Budapest Estetra SRL – Liege • Basic research, 30+ years of • Assets and licenses knowledge in small acquired from Mithra molecule discovery Group • Wide range of synergies on • Development lead platform early an
Slide 16: Neuropsychiatry
Neuropsychiatry CNS 16 16
Slide 17: CNS at a glance at Richter
CNS at a glance at Richter Proven track record of Cariprazine ~1.7 million patients treated worldwide through our network AbbVie – Vraylar net sales (USD mn) Gedeon Richter CEE & RU/CIS, +19% ~4 000 Vietnam Recordati – 3 621 WEU & 3 267 Tunisia 2 670 AbbVie Dexcel 1 978 USA, Israel 1 681 Canada, MPT
Slide 18: Our focus is on disease symptom domains with high prevalence
Our focus is on disease symptom domains with high prevalence GR’s focus diseases GR’s target symptoms Loss of motivation, social withdrawal 7% Major Depression Negative symptoms 2.9% Generalized Anxiety Disorder Problems with executive Cognitive Affective Changes in emotional 2.8% functioning, focus
Slide 19: The success of cariprazine
The success of cariprazine • Oral, once daily atypical antipsychotic discovered by Richter and co-developed with Forest Laboratories (acquired by AbbVie) • Approved indications: USA (Vraylar®): schizophrenia, bipolar mania, bipolar depression, adjunctive therapy to antidepressant for major depressiv
Slide 20: Key Vraylar competitors in the US
Key Vraylar® competitors in the US Major Depression API Bipolar Bipolar Schizophrenia (adjunctive Other indications & information (Brand, Originator) Mania Depression therapy) Cariprazine (Vraylar; AbbVie/Richter) Treatment of agitation associated with Brexpiprazole dementia due to Alzheimer’s (Rexu
Slide 21: Healthy pipeline includes partnered and stand-alone projects
Healthy pipeline includes partnered and stand-alone projects Revenue aspirations from current projects (snapshot, subject to change) Key highlights Expected revenue • Healthy pipeline that gives us confidence we can manage Cariprazine LoE* AbbVie 2022 collaboration effects AbbVie 2024 Cariprazine co
Slide 22: General Medicines
General Medicines GM 22 22
Slide 23: GenMed’s ambition is to establish generics excellence
GenMed’s ambition is to establish generics excellence DOUBLE REVENUE IMPROVE FRESHNESS OF OPERATIONAL EXCELLENCE OUR PORTFOLIO Double revenue by 2035, reach over Continuously bring new products to Run focused cost excellence programs 20% profitability, and remain a key market and improve the freshne
Slide 24: GenMed at a glance
GenMed at a glance GenMed Revenue EUR mn GenMed cEBIT EUR mn GenMed geographic coverage 6% 4.4% 21% HU 634 628 128 PL 594 44% 574 113 12% RO 529 103 Other CE*** 90 93 49% 23% 46% RU 8% UKR 13% UZB Central Europe 10% 67% KAZ Eastern Europe 5% Other 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Ot
Slide 25: Clear focus set regarding therapeutic areas
Clear focus set regarding therapeutic areas AFFORDABLE PILLAR GENMED BIOTECH Traditional Generic therapeutic Loss of exclusivity-driven strategic areas therapeutic areas Cardiovascular Blood therapies Musculoskeletal Traditional CNS Diabetes and Obesity Immunology We have a wide portfolio coverage i
Slide 26: Harnessing speed and scale and rolling it out to Western Europe
Harnessing speed and scale and rolling it out to Western Europe Our aim is to strengthen Generics Excellence at HQ level Broaden our geographic reach to Western Europe • Pursue Portfolio management excellence; BD+L* • Expand our operational excellence • Enhance Development and Regulatory excellence
Slide 27: Strategic ambitions for 2030 and 2035
Strategic ambitions for 2030 and 2035 Doubling cEBIT margin R&D Spend to Revenue Revenue 634 1,300+ 16% 20%+ 5% 7% mn EUR mn EUR 2024 2035 2024 2030 Top5 in key 2024 2030 Freshness countries in index* the core region 8.4% 15%+ 1 4 2024 2030 2024 2035 27 *Freshness index: Revenue share of products la
Slide 28: Biotechnology
Biotechnology BIO 28 28
Slide 29: Fastest growing segment to reach scale and become profitable
Fastest growing segment to reach scale and become profitable STRONG DOUBLE-DIGIT STRONG BIOTECH ENHANCED PARTNERING REVENUE GROWTH PORTFOLIO AND PIPELINE Aspiring double-digit growth and Launch 8 own developments Further build on existing commercial reaching break-even by 2027 establishing ourselves
Slide 30: Biotech at a glance at Richter
Biotech at a glance at Richter Global Biotech Revenue EUR mn Global Teriparatide partner network Other product revenues 161 4 Teriparatide CDMO 137 121 77 105 72 57 53 80 64 65 52 2022 2023 2024 2025 R&D Capability Production sites Number of own Affiliates • Cell line development • Microbial DS* man
Slide 31: Biotech therapeutic areas are focusing on niche market segments
Biotech therapeutic areas are focusing on niche market segments AFFORDABLE PILLAR BIOTECH GENMED Musculoskeletal Immunology Cardiovascular Skin affected Traditional CNS Rheuma- Atopic Psoriatic Psoriatic toid dermatitis arthritis arthritis Axial Blood therapies Osteo- Coltis Morbus spondylo- porosis
Slide 32: Building a strong Biotech portfolio
Building a strong Biotech portfolio* Molecule/ Therapeutic Early CMC Late CMC Expected Indication Originator Clinical dev. Submission Commercial Product area dev. dev. Launch date TERROSA® Musculoskeletal Osteoporosis Marketed Teriparatide JUNOD®/ YAXWER®, Osteoporosis, Marketed ENOBYTM/ Musculoskel
Slide 33: Richter BioLogics Germany – Increased production capacity for microbially expressed Biopharmaceuticals
Richter BioLogics Germany (RB) – Increased production capacity for microbially expressed Biopharmaceuticals Complete Drug Substance Development & Manufacturing from one Source Strain Development Process Development / Process Transfer Clinical Trial Supply Commercial / Optimization Analytical Develop
Slide 34: Mammalian cell expressed DS and DP manufacturing facilities – Debrecen
Mammalian cell expressed Drug Substance (DS) and Drug Product (DP) manufacturing facilities – Debrecen DS DP • 2 x 5000 L stainless steel • Syringe, cartridge, vial filling fermentation capacity (RABS) • 4 x 2000 L single use • Automated freeze drying & 2 x 50 L pilot scale • Variable batch sizes bi
Slide 35: Research and Development
Research and Development R&D 35 35
Slide 36: R&D pipeline – changes during Q4 2025
R&D pipeline – changes during Q4 2025 Market Preclinical phase Clinical phase Regulatory & Launch Phase 1 Phase 2 Phase 3 Own Technology Development Clinical phase Neuropsychiatry Biotechnology Women’s Healthcare Own General Medicines RSL* new discontinued License 36 * Ready-to-Sell Licensed pipelin
Slide 37: Sustainability
Sustainability 37 37
Slide 38: The role and place of ESG in Richter
The role and place of ESG in Richter ESG Governance and main supporting functions Women on Board Supervisory Board Board of Directors Board of Directors ESG Committee 33% CEO 33% IR and ESG Ratio of women in total workforce: 44% EHS Focus areas in ESG HR Legal 38
Slide 39: Sustainable and scalable growth with purpose
Sustainable and scalable growth with purpose ACCESS TO HEALTH ◼ Focusing on unmet needs ◼ New original research for women’s healthcare ◼ Growing availability of Cariprazine globally Access to ◼ Awareness raising programs health ◼ Diverse and expanding portfolio of affordable medicines PEOPLE ◼ Busin
Slide 40: GHG emissions: declining trend and progress towards targets
GHG emissions: declining trend and progress towards targets Richter Group carbon footprint (Scope 1-2-3, kt CO2eq/year) Key Environmental messages -5.9% +4.8% -3.7% -9.6% 341 337 Group-level GHG emissions decreased materially in 2025 321 324 293 ➢ Nearly 10% reduction in total greenhouse gas emissio
Slide 41: ESG focused initiatives
ESG focused initiatives Preservation of natural resources: optimization of water consumption Water consumption in Richter, Hungary Efficient water consumption 1992-2024 1000m3 • Continuous reduction in water consumption by: 4,500 4,000 ➢ Process optimization for efficient water use in our technologi
Slide 42: Steroids and other pharmaceuticals in wastewater – well below the safety threshold
Steroids and other pharmaceuticals in wastewater – well below the safety threshold PEC/PNEC* Pharmaceuticals in the environment API / intermediates Site Roll-out (acceptable value <1) estetrol Dorog 2022 0.000042 • Following the working out and acceptance of a risk assessment system and methodology,
Slide 43: Diversity vision
Diversity vision The presence of diverse experience, Key initiatives: knowledge, professional background, skills, opinions and thoughts enables us to elevate • Analysis of existing • Focus groups on • DEI the standard of care in key therapeutic Mapping DEI HR data and special issues and/or organizat
Slide 44: Risk management framework
Risk management framework Integral part of Richter's activities and corporate governance system Regular reports to decision-making bodies Independent risk management function Holistic and integrated risk management system Connected to the realization of strategic goals Rules, regulations, limits, co
Slide 45: Key financial, strategic and operational risks
Key financial, strategic and operational risks Financial risks Main strategic and operational risks Risk Mitigation Risk Mitigation Hedging strategy, early/long-term pre-order, accurate planning, V Currency risk V H natural hedges, shorter customer H Supply chain risk* long-term forecasts, alternati
Slide 46: Financials
Financials © @ GEDEON RICHTER
Slide 47: Pharma revenues and Clean EBIT
Pharma revenues and Clean EBIT Pharma Revenues, 2021-25 (EUR mn) Clean EBIT, 2021-2025 (EUR mn) WHC BIO Other WHC BIO Other Clean EBIT GM CNS GM CNS margin % 28.3% 31.4% 31.6% 31.5% 33.3% 2,298 +13% 2,136 766 1,957 +18% 674 826 134 1,667 724 619 102 669 103 93 1,408 525 90 582 117 113 461 628 398 63
Slide 48: Ex-CNS Revenues to more than double by 2035
Ex-CNS Revenues to more than double by 2035 Pharma Revenues 2020-2035 (EUR bn) CNS ~7-8% CAGR (ex-CNS) Pharma-ex CNS 2.3 2.1 0.7 0.6 ~3.2-3.5 ~2.2-2.4 1.5 1.6 2021 2022 2023 2024 2025 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E 2035E Key highlights • All projections are based on organic gr
Slide 49: Steady-state cEBIT margin to exceed 20% in the 30s
Steady-state cEBIT margin to exceed 20% in the 30s Clean EBIT margin between 2023-2035E (%) 40 cEBIT margin (ex-CNS) 35 cEBIT margin 30 25 20 15 11.3% 9.5% 8.9% 10 5 0 2023 2024 2025 2031E 2035E Key highlights • Years of portfolio and capability building, coupled with operational excellence and effi
Slide 50: The heavy lifting has to happen until LoE
The heavy lifting has to happen until LoE The source of the margin improvement (cEBIT margin ex-CNS, %) ~+2ppt ~+11ppt 22%+ 20%+ 8.9% 2024A Self- Commercial Commercial G&A Portfolio Operational Infrastructure 2031E R&D step-up Portfolio Biotech CAPEX 2035E sufficient excellence footprint complexity
Slide 51: Capital allocation priorities: R&D, external innovation, shareholders
Capital allocation priorities: R&D, external innovation, shareholders Key highlights • More for R&D – R&D will be the biggest use of cash in 2025-35 with c. 30-35% of pre-R&D cash spent • Less for Capex (physical infrastructure) and NWC - proportionally much less spend than in the last 5 years • Ext
Slide 52: Capital allocation – balancing between predictability and flexibility
Capital allocation – balancing between predictability and flexibility Protecting shareholders’ interest and providing an attractive income stream • Richter can sustain paying at least EUR 200mn annual dividends in 2025-35, even beyond Vraylar LoE • Richter to pay out 30-50% of its adjusted net incom
Slide 53: Sustainable long-term dividend with material upside through 2030
Sustainable long-term dividend with material upside through 2030 A conceptual path to future dividends (EUR mn, all hypothetical values beyond 2024) Dividend per share, payout ratio (HUF; %) Dividend Min. dividend 600 100 Dividend upside 509 90 30% payout 500 80 432 50% payout 391 70 400 60 47 49 30
Slide 54: Shareholders structure
Shareholders structure 6% 5% 7% 10% International institutional investors Domestic institutional investors 10% Retail investors Free float: Foundation for National Health and Education of Medical Doctors ~73% 2% Maecenas Universitatis Corvini Foundation Mathias Corvinus Collegium Foundation Treasury
Slide 55: Executive compensation overview
Executive compensation overview Short-term incentive: CEO KPIs Short-term incentive is an annual bonus set as a fixed % of the salary CEO and CFO payout breakdown in 2024 based on the executive’s job level. Main KPIs: • Clean Ebit growth • New product registration/launch 4% 8% • Key/flagship product
Slide 56: Q4 2025 update
Q4 2025 update 56 56
Slide 57: 2025 highlights – strong finish to the year, beating cEBIT guidance
2025 highlights – strong finish to the year, beating cEBIT guidance 2025 CER revenue growth was 8.3% (to guidance Pharma Revenues (CER*) close to EUR 2.3bn EUR 2.31bn) 2025 1 Clean EBIT (CER*) + 8-10% 2025 CER Clean EBIT growth was 14% Q1 HUF 914.0bn HUF 306.2bn HUF 292.9bn 1 EBIT: Profit/loss from
Slide 58: Pharmaceutical revenues (CER) rose by 8.3% in 2025
Pharmaceutical revenues (CER) rose by 8.3% in 2025 Pharmaceutical Revenues, cumulative (HUF bn) Pharmaceutical Revenues by region (HUF bn) +8.2% +8.3% Western Europe 156.2 179.0 914.0 914.8 844.8 Central Europe 174.3 Pharma other 176.4 GM Eastern Europe 172.9 185.8 BIO 255.3 North America 276.4 WHC
Slide 59: Very strong Q4 boosts full-year CER Clean EBIT growth to 14%
Very strong Q4 boosts full-year CER Clean EBIT growth to 14% Pharmaceutical Clean EBIT*, cumulative (HUF bn) Key messages +14.3% +14.2% • Clean EBIT (pharma) jumped by 37% YoY in Q4 2025 (from 304.7 a rather low base) to HUF 92bn, bringing full-year 2025 304.4 Clean EBIT to HUF 305bn, up 14.3% YoY 2
Slide 60: Below-the-line: FX losses and non-recurring tax items
Below-the-line: FX losses and non-recurring tax items Net Profit in 2025, below-Clean EBIT items (HUF bn) Includes taxes calculated in line with 306.2 Global Minimum Tax, some deferred -13.3 292.9 tax expenses (HUF 5bn), tax 2.7 provisions (HUF 3bn) and the -25.3 7.8 contribution of higher-tax count
Slide 61: Sustained robust cash generation in 2025
Sustained robust cash generation in 2025 Free Cash Flow in 2025 (HUF bn) Key messages NWC increased by HUF 17bn in Q4, reversing the Q3 decline as Application of Cash Flow • Free Cash Flow was HUF 250bn in 2025, activity level normalized 308.6 slightly higher YoY (+2%). Stronger 32.2 276.4 operating
Slide 62: 2026 guidance and outlook
2026 guidance and outlook ▪ At current spot FX rates, reported revenues would see High-single-digit guidance around 5ppt headwind Pharma Revenues (CER**) growth 2026 ▪ R&D-to-sales to be around 11% in 2026 ▪ Adjusted „Clean EBIT” methodology* High-single-digit ▪ c. EUR 100mn restructuring expenses e
Slide 63: Leadership team
Leadership team Gábor Orbán László András Kovács Dr István Greiner CEO CFO R&D Director Appointed Chief Executive Officer from Graduated at Corvinus University Budapest Appointed Research Director in 2014. November 1, 2017. Began his professional in 2006. He began his career at PwC Chemical engineer
Slide 64: Leadership team
Leadership team Katalin Erdei Attila Szénási Tamás Szolyák HR & Technical Director Chief Operating Officer Commercial Director After graduating at the University of Szeged Joined the Company in 2019 as Director Joined the company in September 2018 as from the Faculty of Arts, and pursuing of Pharmac
Slide 65: References
References Women’s Healthcare 1 https://www.grandviewresearch.com/industry-analysis/womens-health-market 2 (a) https://ec.europa.eu/eurostat/statistics-explained/index.php?oldid=664290 (b) https://data.worldbank.org/indicator/SP.DYN.TFRT.IN?locations=US 3 https://www.grandviewresearch.com/industry-a
Slide 66: Contacts and Financial calendar
Contacts Financial calendar Company name: Gedeon Richter Plc. | 29 April 2026 – Annual General Meeting Sector: Pharmaceutical | 12 May 2026 – Q1 2026 results Company address: 1103 Budapest, Gyömrői út 19-21., Hungary | 7 August 2026 – H1 2026 results Telephone: +36 1 431 5764 | 10 November 2026 – Q3
Slide 67: Disclaimer
Disclaimer This presentation may contain forward-looking statements, that may include, but are not limited to, those regarding capital, investment, cash flows, demand, earnings, efficiency, production, profits. These forward-looking statements are subject to risks, uncertainties, and other factors,